Jiyang Yu, Ph.D. - Publications

Affiliations: 
Biomedical Informatics Columbia University, New York, NY 
Area:
gene regulatory models

51 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Dong X, Ding L, Thrasher A, Wang X, Liu J, Pan Q, Rash J, Dhungana Y, Yang X, Risch I, Li Y, Yan L, Rusch M, McLeod C, Yan KK, ... ... Yu J, et al. NetBID2 provides comprehensive hidden driver analysis. Nature Communications. 14: 2581. PMID 37142594 DOI: 10.1038/s41467-023-38335-6  0.486
2023 Luo Z, Xin D, Liao Y, Berry K, Ogurek S, Zhang F, Zhang L, Zhao C, Rao R, Dong X, Li H, Yu J, Lin Y, Huang G, Xu L, ... ... Yu J, et al. Loss of phosphatase CTDNEP1 potentiates aggressive medulloblastoma by triggering MYC amplification and genomic instability. Nature Communications. 14: 762. PMID 36765089 DOI: 10.1038/s41467-023-36400-8  0.496
2022 Zeleke TZ, Pan Q, Chiuzan C, Onishi M, Li Y, Tan H, Alvarez MJ, Honan E, Yang M, Chia PL, Mukhopadhyay P, Kelly S, Wu R, Fenn K, Trivedi MS, ... ... Yu J, et al. Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer. Nature Cancer. PMID 36585452 DOI: 10.1038/s43018-022-00489-5  0.547
2022 Roussel MF, Jonchere B, Williams J, Zindy F, Liu J, Robinson S, Farmer DM, Min J, Yang L, Stripay JL, Wang Y, Freeman BB, Yu J, Shelat AA, Rankovic Z. Combination of ribociclib with BET-bromodomain and PI3K/mTOR inhibitors for medulloblastoma treatment in vitro and in vivo. Molecular Cancer Therapeutics. PMID 36318650 DOI: 10.1158/1535-7163.MCT-21-0896  0.316
2022 Zhao X, Wang P, Diedrich JD, Smart B, Reyes N, Yoshimura S, Zhang J, Yang W, Barnett K, Xu B, Li Z, Huang X, Yu J, Crews K, Yeoh AEJ, et al. Epigenetic activation of the FLT3 gene by ZNF384 fusion confers a therapeutic susceptibility in acute lymphoblastic leukemia. Nature Communications. 13: 5401. PMID 36104354 DOI: 10.1038/s41467-022-33143-w  0.347
2022 Chaudhary KR, Kinslow CJ, Cheng H, Silva JM, Yu J, Wang TJ, Hei TK, Halmos B, Cheng SK. Smurf2 inhibition enhances chemotherapy and radiation sensitivity in non-small-cell lung cancer. Scientific Reports. 12: 10140. PMID 35710591 DOI: 10.1038/s41598-022-14448-8  0.301
2021 Luo Z, Dong X, Yu J, Xia Y, Berry KP, Rao R, Xu L, Xue P, Chen T, Lin Y, Yu J, Huang G, Li H, Zhou W, Lu QR. Genomic and Transcriptomic Analyses Reveals ZNF124 as a Critical Regulator in Highly Aggressive Medulloblastomas. Frontiers in Cell and Developmental Biology. 9: 634056. PMID 33681213 DOI: 10.3389/fcell.2021.634056  0.517
2020 Autry RJ, Paugh SW, Carter R, Shi L, Liu J, Ferguson DC, Lau CE, Bonten EJ, Yang W, McCorkle JR, Beard JA, Panetta JC, Diedrich JD, Crews KR, Pei D, ... ... Yu J, et al. Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia. Nature Cancer. 1: 329-344. PMID 32885175 DOI: 10.1038/S43018-020-0037-3  0.392
2020 Tosello V, Bongiovanni D, Liu J, Pan Q, Yan KK, Saccomani V, Van Trimpont M, Pizzi M, Mazzoni M, Dei Tos AP, Amadori A, Zanovello P, Van Vlierberghe P, Yu J, Piovan E. Cross-talk between GLI transcription factors and FOXC1 promotes T-cell acute lymphoblastic leukemia dissemination. Leukemia. PMID 32733009 DOI: 10.1038/S41375-020-0999-2  0.389
2020 Hao Shi, Yan KK, Ding L, Qian C, Chi H, Yu J. Network Approaches for Dissecting the Immune System. Iscience. 23: 101354. PMID 32717640 DOI: 10.1016/J.Isci.2020.101354  0.316
2020 Marks DK, Gartrell RD, El Asmar M, Boboila S, Hart T, Lu Y, Pan Q, Yu J, Hibshoosh H, Guo H, Andreopoulou E, Wiechmann L, Crew K, Sparano J, Hershman D, et al. Akt Inhibition Is Associated With Favorable Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor Positive, HER2 Negative Breast Cancer. Frontiers in Oncology. 10: 968. PMID 32612958 DOI: 10.3389/Fonc.2020.00968  0.368
2020 Wijaya J, Vo BT, Liu J, Xu B, Wu G, Wang Y, Peng J, Zhang J, Janke LJ, Orr BA, Yu J, Roussel MF, Schuetz JD. An ABC transporter drives medulloblastoma pathogenesis by regulating Sonic Hedgehog signaling. Cancer Research. PMID 31948942 DOI: 10.1158/0008-5472.Can-19-2054  0.397
2020 Silva J, Kalinsky K, Chiuzan C, Zeleke T, Qingfei P, Yu J. Abstract CT107: Phase IB trial of ACY-1215 (ricolinostat) combined with nab-paclitaxel in metastatic breast cancer (MBC) Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Ct107  0.425
2019 Yu J, Peng J, Chi H. Systems immunology: Integrating multi-omics data to infer regulatory networks and hidden drivers of immunity. Current Opinion in Systems Biology. 15: 19-29. PMID 32789283 DOI: 10.1016/J.Coisb.2019.03.003  0.318
2019 Wei J, Long L, Zheng W, Dhungana Y, Lim SA, Guy C, Wang Y, Wang YD, Qian C, Xu B, Kc A, Saravia J, Huang H, Yu J, Doench JG, et al. Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy. Nature. PMID 31827283 DOI: 10.1038/S41586-019-1821-Z  0.39
2019 Mamcarz E, Zhou S, Lockey T, Boi S, Koon-Kiu Y, Cross S, Kang G, Ma Z, Condori JM, Dowdy J, Metais J, Langfitt D, Triplett B, Li C, Zhao X, ... ... Yu J, et al. Lentiviral Gene Therapy with Low Dose Busulfan for Infants with X-SCID Results in the Development of a Functional Normal Immune System: Interim Results of an Ongoing Phase I/II Clinical Study Blood. 134: 2058-2058. DOI: 10.1182/Blood-2019-126746  0.312
2019 Shaw TI, Dong L, High A, Liu Y, Ju B, Kavdia K, Pagala V, Shaner B, Easton J, Qian C, Yu J, Janke J, Choi JK, Peng J, Gu W, et al. Abstract 3652: USP7 heterozygous loss-of-function affects T-cell differentiation in pediatric T-ALL Cancer Research. 79: 3652-3652. DOI: 10.1158/1538-7445.Am2019-3652  0.35
2018 Khatamian A, Paull EO, Califano A, Yu J. SJARACNe: a scalable software tool for gene network reverse engineering from big data. Bioinformatics (Oxford, England). PMID 30388204 DOI: 10.1093/Bioinformatics/Bty907  0.499
2018 Boboila S, Lopez G, Yu J, Banerjee D, Kadenhe-Chiweshe A, Connolly EP, Kandel JJ, Rajbhandari P, Silva JM, Califano A, Yamashiro DJ. Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastoma. Oncogene. PMID 29880876 DOI: 10.1038/S41388-018-0326-9  0.593
2018 Du X, Wen J, Wang Y, Karmaus PWF, Khatamian A, Tan H, Li Y, Guy C, Nguyen TM, Dhungana Y, Neale G, Peng J, Yu J, Chi H. Hippo/Mst signalling couples metabolic state and immune function of CD8α dendritic cells. Nature. PMID 29849151 DOI: 10.1038/S41586-018-0177-0  0.344
2018 Yu J, Silva JM. Bayesian Network to Infer Drug-Induced Apoptosis Circuits from Connectivity Map Data. Methods in Molecular Biology (Clifton, N.J.). 1783: 361-378. PMID 29767372 DOI: 10.1007/978-1-4939-7834-2_18  0.391
2018 Rajbhandari P, Lopez G, Capdevila C, Salvatori B, Yu J, Rodriguez-Barrueco R, Martinez D, Yarmarkovich M, Weichert-Leahey N, Abraham BJ, Alvarez MJ, Iyer A, Harenza JL, Oldridge D, De Preter K, et al. Cross-cohort analysis identifies a TEAD4 ↔ MYCN positive-feedback loop as the core regulatory element of high-risk neuroblastoma. Cancer Discovery. PMID 29510988 DOI: 10.1158/2159-8290.Cd-16-0861  0.554
2018 Kalinsky K, Onishi M, Yu J, Trivedi MS, Accordino MK, Crew KD, Hershman DL, Maurer MA, Silva J. Phase IB trial of ACY-1215 (Ricolinostat) combined with nab-paclitaxel in metastatic breast cancer. Journal of Clinical Oncology. 36: 1058-1058. DOI: 10.1200/Jco.2018.36.15_Suppl.1058  0.337
2018 Zeleke TZ, Putcha P, Yu J, Califano A, Silva JM. Abstract 2898: Inhibition of HDAC6 as a novel targeted therapy in breast cancer Cancer Research. 78: 2898-2898. DOI: 10.1158/1538-7445.Am2018-2898  0.616
2017 Putcha P, Yu J, Rodriguez-Barrueco R, Saucedo-Cuevas L, Villagrasa P, Murga-Penas E, Quayle SN, Yang M, Castro V, Llobet-Navas D, Birnbaum D, Finetti P, Woodward WA, Bertucci F, Alpaugh ML, et al. Erratum to: HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers. Breast Cancer Research : Bcr. 19: 49. PMID 28424080 DOI: 10.1186/S13058-017-0841-6  0.549
2017 Rodriguez-Barrueco R, Nekritz EA, Bertucci F, Yu J, Sanchez-Garcia F, Zeleke TZ, Gorbatenko A, Birnbaum D, Ezhkova E, Cordon-Cardo C, Finetti P, Llobet-Navas D, Silva JM. miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy. Genes & Development. 31: 553-566. PMID 28404630 DOI: 10.1101/Gad.292318.116  0.374
2017 Yu J, Silva JM, Califano A. Abstract PR10: ScreenBEAM: a Novel Meta-Analysis Algorithm for Functional Genomics Screens via Bayesian Hierarchical Modeling Molecular Cancer Therapeutics. 16. DOI: 10.1158/1538-8514.Synthleth-Pr10  0.553
2016 Tosello V, Saccomani V, Yu J, Bordin F, Amadori A, Piovan E. Calcineurin complex isolated from T-cell acute lymphoblastic leukemia (T-ALL) cells identifies new signaling pathways including mTOR/AKT/S6K whose inhibition synergize with Calcineurin inhibition to promote T-ALL cell death. Oncotarget. PMID 27304189 DOI: 10.18632/Oncotarget.9933  0.391
2016 Yu J, Califano A, silva j. Abstract B36: Inhibition of the autocrine IL-6-JAK2-STAT3-Calprotectin axis as targeted therapy for HR-/HER2+ breast cancers Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Advbc15-B36  0.622
2016 Putcha P, Yu J, Rodriguez-Barrueco R, Califano A, silva j. Abstract A71: HDAC6 activity is a non-oncogene addiction hub for in inflammatory breast cancers Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Advbc15-A71  0.628
2016 Rajbhandari P, Lopez G, Yu J, Rodriguez-Barrueco R, Alvarez M, Martinez D, Yarmarkovich M, Vandesompele J, Mestdagh P, Silva JM, Lasorella A, Iavarone A, Maris JM, Califano A. Abstract 4384: Selective cross-cohort discovery of transcriptional mechanisms presiding over high-risk neuroblastoma subtype state maintenance Cancer Research. 76: 4384-4384. DOI: 10.1158/1538-7445.Am2016-4384  0.603
2015 Cheng H, Zhang Z, Rodriguez-Barrueco R, Borczuk A, Liu H, Yu J, Silva JM, Cheng SK, Perez-Soler R, Halmos B. Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells. Oncotarget. PMID 26716514 DOI: 10.18632/Oncotarget.6721  0.391
2015 Tosello V, Bordin F, Yu J, Agnusdei V, Indraccolo S, Basso G, Amadori A, Piovan E. Calcineurin and GSK-3 inhibition sensitizes T-cell acute lymphoblastic leukemia cells to apoptosis through X-linked inhibitor of apoptosis protein (XIAP) degradation. Leukemia. PMID 26648536 DOI: 10.1038/Leu.2015.335  0.357
2015 Putcha P, Yu J, Rodriguez-Barrueco R, Saucedo-Cuevas L, Villagrasa P, Murga-Penas E, Quayle SN, Yang M, Castro V, Llobet-Navas D, Birnbaum D, Finetti P, Woodward WA, Bertucci F, Alpaugh ML, et al. HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers. Breast Cancer Research : Bcr. 17: 149. PMID 26643555 DOI: 10.1186/S13058-015-0658-0  0.639
2015 Yu J, Silva J, Califano A. ScreenBEAM: a Novel Meta-Analysis Algorithm for Functional Genomics Screens via Bayesian Hierarchical Modeling. Bioinformatics (Oxford, England). PMID 26415723 DOI: 10.1093/Bioinformatics/Btv556  0.544
2015 O'Brien SK, Chen L, Zhong W, Armellino D, Yu J, Loreth C, Follettie M, Damelin M. Breast cancer cells respond differentially to modulation of TGF-β2 signaling after exposure to chemotherapy or hypoxia. Cancer Research. PMID 26340918 DOI: 10.1158/0008-5472.Can-15-0650  0.431
2015 Rodriguez-Barrueco R, Yu J, Saucedo-Cuevas LP, Olivan M, Llobet-Navas D, Putcha P, Castro V, Murga-Penas EM, Collazo-Lorduy A, Castillo-Martin M, Alvarez M, Cordon-Cardo C, Kalinsky K, Maurer M, Califano A, et al. Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancers. Genes & Development. 29: 1631-48. PMID 26227964 DOI: 10.1101/Gad.262642.115  0.613
2015 Yu J, Putcha P, Silva JM. Recovering drug-induced apoptosis subnetwork from Connectivity Map data. Biomed Research International. 2015: 708563. PMID 25883971 DOI: 10.1155/2015/708563  0.404
2015 Sato M, Rodriguez-Barrueco R, Yu J, Do C, Silva JM, Gautier J. MYC is a critical target of FBXW7. Oncotarget. 6: 3292-305. PMID 25669969 DOI: 10.18632/Oncotarget.3203  0.47
2015 Zhang S, Lopez G, Yu J, Silva J, Kadenhe-Chiweshe A, Califano A, Yamashiro D. Abstract 2083: TFAP4 inhibits differentiation of MYCN-amplified neuroblastoma Cancer Research. 75: 2083-2083. DOI: 10.1158/1538-7445.Am2015-2083  0.574
2014 Putcha P, Yu J, Califano A, Silva J. Abstract 4623: HDAC6 inhibition is a novel strategy to selectively impact inflammatory breast cancer cell survival Cancer Research. 74: 4623-4623. DOI: 10.1158/1538-7445.Am2014-4623  0.618
2014 Barrueco RR, Yu J, Alvarez M, Castro V, Marshall N, Su R, Castro L, Maurer M, Califano A, Silva JM. Abstract 2761: Characterizing the mechanism and the clinical relevance of the synthetic lethal interaction between STAT3 inhibition and HER2 overexpression in breast cancers Cancer Research. 74: 2761-2761. DOI: 10.1158/1538-7445.Am2014-2761  0.647
2013 Piovan E, Yu J, Tosello V, Herranz D, Ambesi-Impiombato A, Da Silva AC, Sanchez-Martin M, Perez-Garcia A, Rigo I, Castillo M, Indraccolo S, Cross JR, de Stanchina E, Paietta E, Racevskis J, et al. Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. Cancer Cell. 24: 766-76. PMID 24291004 DOI: 10.1016/J.Ccr.2013.10.022  0.534
2013 Yu J, Putcha P, Califano A, Silva JM. Pooled shRNA screenings: computational analysis. Methods in Molecular Biology (Clifton, N.J.). 980: 371-84. PMID 23359167 DOI: 10.1007/978-1-62703-287-2_22  0.517
2013 Cheng H, Zhang Z, Rodriguez-Barrueco R, Yu J, Silva JM, Cheng S, Perez-Soler R, Halmos B. Abstract 2044: Down-regulation of YAP sensitizes lung cancer cells to platinum and ionizing radiation. Cancer Research. 73: 2044-2044. DOI: 10.1158/1538-7445.Am2013-2044  0.452
2013 Rodriguez-Barrueco R, Yu J, Alvarez M, Castro V, Villagrasa P, Marshall N, Sun R, Castro L, Califano A. Abstract PR11: Characterizing the mechanism and the clinical relevance of the synthetic lethal interaction between STAT3 inhibition and HER2 overexpression in breast cancers Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Pms-Pr11  0.654
2013 Yu J, Gao Y, Zhong W, Chen L, Apanovitch D, Follettie M, Rejto P, Arndt K. Abstract A33: Optimizing NGS-based shRNA screening experiments and data analysis Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Pms-A33  0.397
2012 Yu J, Piovan E, Flaherty MS, Silva J, Ferrando A, Califano A. Abstract A35: Discovery of driver-type therapeutic targets to reverse glucocorticoid resistance in T-ALL Cancer Research. 72. DOI: 10.1158/1538-7445.Csb12-A35  0.569
2010 Piovan E, Yu J, Real P, Ann GM, Califano A, Ferrando A. Oncogenic AKT Signaling Negatively Regulates Glucocorticoid Receptor Function to Promote Glucocorticoid Resistance In T Cell Acute Lymphoblastic Leukemia Blood. 116: 11-11. DOI: 10.1182/Blood.V116.21.11.11  0.57
2009 Lü B, Yu J, Xu J, Chen J, Lai M. A novel approach to detect differentially expressed genes from count-based digital databases by normalizing with housekeeping genes. Genomics. 94: 211-6. PMID 19446020 DOI: 10.1016/J.Ygeno.2009.05.003  0.39
2008 Lü B, Xu J, Chen J, Yu J, Xu E, Lai M. TaqMan low density array is roughly right for gene expression quantification in colorectal cancer. Clinica Chimica Acta; International Journal of Clinical Chemistry. 389: 146-51. PMID 18179774 DOI: 10.1016/J.Cca.2007.12.009  0.361
Show low-probability matches.